临床实践
Copyright ©The Author(s) 2022.
世界华人消化杂志. 2022-12-28; 30(24): 1079-1085
在线出版 2022-12-28. doi: 10.11569/wcjd.v30.i24.1079
表1 胃癌组织及癌旁组织Her-2、CyclinD1、miR-223表达量对比(mean±SD)
组别胃癌组织(n = 54)癌旁组织(n = 54)tP
Her-20.95±0.240.52±0.1311.577<0.001
CyclinD10.64±0.230.27±0.1210.481<0.001
miR-2234.31±0.780.94±0.2130.658<0.001
表2 不同病理特征胃癌H. pylori感染患者Her-2、CyclinD1、miR-223表达对比(mean±SD)
组别例数Her-2t/P/rCyclinD1t/P/rmiR-223t/P/r
分化程度高-中分化230.94±0.272.170/0.037/0.5270.61±0.124.386/<0.001/0.6325.02±1.253.718/<0.001/0.702
低-未分化141.15±0.310.80±0.146.74±1.54
浸润深度T1+T2140.92±0.152.898/0.006/0.6180.62±0.122.113/<0.042/0.6744.89±0.823.825/<0.001/0.684
T3+T4231.08±0.170.72±0.156.14±1.04
TNM分期Ⅰ、Ⅱ160.91±0.212.450/0.019/0.5960.61±0.142.383/0.023/0.6585.04±0.943.141/0.003/0.632
Ⅲ、Ⅳ211.10±0.250.73±0.166.15±1.15
淋巴结转移180.96±0.132.594/0.014/0.6040.63±0.122.428/0.021/0.6215.12±0.923.081/0.004/0.597
191.08±0.150.73±0.136.19±1.17
表3 H. pylori感染与未感染胃癌患者临床资料对比
指标H. pylori感染(n = 37)未感染(n = 17)χ2P
年龄
<6017(45.95)7(41.18)0.1070.743
≥6020(54.05)10(58.82)
性别
21(56.76)13(76.47)1.9410.164
16(43.24)4(23.53)
肿瘤大小
≤5 cm22(59.46)10(58.82)0.0020.965
>5 cm15(40.54)7(41.18)
分化程度
高-中分化23(62.16)11(64.71)0.0320.857
低-未分化14(37.84)6(35.29)
浸润深度
T1+T214(37.84)12(70.59)5.0040.025
T3+T423(62.16)5(29.41)
临床分期
Ⅰ、Ⅱ16(43.24)6(35.29)0.3050.581
Ⅲ、Ⅳ21(56.76)11(64.71)
肿瘤位置
贲门、胃底10(27.03)5(29.41)0.0860.958
胃体8(21.62)4(23.53)
胃窦19(51.35)8(47.06)
淋巴结转移
18(48.65)14(82.35)5.4810.019
19(51.35)3(17.65)
胃癌分型
肠型胃癌30(81.08)6(35.29)28.595<0.001
弥漫性胃癌7(18.92)11(64.71)
表4 H. pylori感染与未感染患者胃癌组织Her-2、CyclinD1、miR-223表达(mean±SD)
指标H. pylori感染(n = 37)未感染(n = 17)tP
Her-21.02±0.310.80±0.242.5870.013
CyclinD10.68±0.150.55±0.123.1370.003
miR-2235.67±1.241.35±0.3214.083<0.001

引文著录: 陈进强, 马佳红. 幽门螺杆菌感染与胃癌组织Her-2、CyclinD1、miR-223的相关性及对肿瘤侵袭性的影响. 世界华人消化杂志 2022; 30(24): 1079-1085